Literature DB >> 17323424

Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B.

K Mori1,2, B Le Goff1,2, M Berreur1,2, A Riet1,2, A Moreau3, F Blanchard1,2, C Chevalier4, I Guisle-Marsollier4, J Léger4, J Guicheux5, M Masson5, F Gouin1,2,6, F Rédini1,2, D Heymann1,2.   

Abstract

RANK, RANK ligand (RANKL) and osteoprotegerin (OPG) are the key regulators of bone metabolism, both in normal and pathological conditions. Previous data have demonstrated that human osteosarcoma biopsies express RANKL as well as OPG, and functional RANK is expressed in a murine osteosarcoma cell line. As RANK expression in human osteosarcoma remains controversial, the aim of the present study was to analyse its expression in vitro in human osteosarcoma cell lines, ex vivo using pathological tissues, and then to determine its functionality in terms of signal transduction pathways modulated by RANKL. RT-PCR analysis and immunohistochemistry experiments revealed that RANK is expressed at both transcriptional and protein levels in MNNG/HOS, Saos-2 and MG-63 human osteosarcoma cell lines, in contrast to the U-2 OS osteosarcoma cell line and human osteoblasts, which were negative. RANK was also expressed in 57% of osteosarcoma biopsies. Furthermore, western blot experiments clearly demonstrated the functionality of RANK. Thus, RANKL significantly induced the phosphorylation of ERK1/2, p38 and IkappaB in RANK-positive osteosarcoma cells. This study is the first report of functional RANK expression in human osteosarcoma cells: this strengthens the involvement of the RANK-RANKL-OPG axis in primary bone tumour biology and identifies novel therapeutic approaches targeting RANK-positive osteosarcoma. Copyright (c) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17323424     DOI: 10.1002/path.2140

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  32 in total

1.  Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro.

Authors:  Lysann Michaela Kroschwald; Josephine Tabea Tauer; Sonja Ingrid Kroschwald; Meinolf Suttorp; Anne Wiedenfeld; Stefan Beissert; Andrea Bauer; Martina Rauner
Journal:  Oncol Lett       Date:  2019-06-21       Impact factor: 2.967

2.  RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells.

Authors:  Toru Akiyama; Peter F M Choong; Crispin R Dass
Journal:  Clin Exp Metastasis       Date:  2010-04-11       Impact factor: 5.150

Review 3.  Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.

Authors:  Maria V Deligiorgi; Mihalis I Panayiotidis; John Griniatsos; Dimitrios T Trafalis
Journal:  Clin Exp Metastasis       Date:  2019-10-01       Impact factor: 5.150

4.  Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease.

Authors:  Sumit K Sood; Sabapathy Balasubramanian; Sue Higham; Malee Fernando; Barney Harrison
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

Review 5.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 6.  Deciphering signaling networks in osteosarcoma pathobiology.

Authors:  Christos Adamopoulos; Antonios N Gargalionis; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-06

7.  Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells.

Authors:  Jun Chang; Wei Wang; Hui Zhang; Yong Hu; Zongsheng Yin
Journal:  Oncol Lett       Date:  2012-05-21       Impact factor: 2.967

Review 8.  RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors:  Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal:  Curr Drug Discov Technol       Date:  2008-09

Review 9.  Advances in the Management of Pediatric Sarcomas.

Authors:  Fiorela N Hernandez Tejada; Alejandro Zamudio; Mario L Marques-Piubelli; Branko Cuglievan; Douglas Harrison
Journal:  Curr Oncol Rep       Date:  2020-11-16       Impact factor: 5.075

10.  Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma.

Authors:  François Lamoureux; Gaëlle Picarda; Julie Rousseau; Clothilde Gourden; Séverine Battaglia; Céline Charrier; Bruno Pitard; Dominique Heymann; Françoise Rédini
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.